Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CELLCEPT vs AZATHIOPRINE SODIUM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Mycophenolate mofetil is a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), inhibiting de novo purine synthesis in T and B lymphocytes, thereby suppressing lymphocyte proliferation.
Azathioprine is a prodrug of 6-mercaptopurine. It inhibits purine synthesis by interfering with the synthesis of DNA, RNA, and cellular proteins, thereby suppressing immune responses.
Prophylaxis of organ rejection in renal transplant recipients,Prophylaxis of organ rejection in cardiac transplant recipients,Prophylaxis of organ rejection in hepatic transplant recipients,Off-label: Treatment of lupus nephritis, autoimmune diseases, and other transplant indications
Renal transplantation (adjunctive immunosuppression),Rheumatoid arthritis (active, severe, not responsive to conventional therapy),Off-label: Inflammatory bowel disease (Crohn's disease, ulcerative colitis), autoimmune hepatitis, systemic lupus erythematosus, vasculitis, myasthenia gravis, pemphigus vulgaris
Oral: 1-2 g daily in two divided doses. Intravenous: 1-2 g daily in two divided doses as a 2-hour infusion.
1-2 mg/kg/day IV or oral, initially; maintenance 0.5-1 mg/kg/day IV or oral. For severe organ rejection: 3-5 mg/kg/day IV.
Terminal elimination half-life of MPA is approximately 17.9 ± 6.5 hours in renal transplant patients. Clinical significance: dosing interval of 12 hours maintains therapeutic levels.
Terminal elimination half-life of azathioprine is approximately 3-5 hours; its active metabolite 6-mercaptopurine has a half-life of 0.5-1.5 hours. However, the pharmacodynamic effect (immunosuppression) persists longer due to intracellular accumulation of thioguanine nucleotides.
Mycophenolate mofetil is hydrolyzed to mycophenolic acid (MPA), the active metabolite. MPA is primarily metabolized by glucuronidation via UDP-glucuronosyltransferases (UGT1A9 and UGT2B7) to MPA-glucuronide (MPAG), which is excreted in urine.
Primarily metabolized by xanthine oxidase (XO) and thiopurine methyltransferase (TPMT) to active and inactive metabolites. Also metabolized by aldehyde oxidase and glutathione S-transferase. Concomitant use with allopurinol (XO inhibitor) requires dose reduction.
Mycophenolic acid (MPA) is primarily excreted in urine as mycophenolic acid glucuronide (MPAG) (87% of dose); <1% excreted as unchanged MPA. Fecal excretion accounts for approximately 6% of dose.
Primarily renal: approximately 50% as unchanged drug and metabolites (6-mercaptopurine, thiouric acid) within 24 hours. Biliary/fecal excretion accounts for minor fraction (<5%).
97% bound to albumin. In renal impairment or hypoalbuminemia, free fraction increases.
Approximately 30% bound to serum proteins, primarily albumin.
Apparent volume of distribution of MPA is approximately 3.6 L/kg (range 1.5-5.0 L/kg), indicating extensive tissue distribution.
Apparent volume of distribution is 0.6-1.0 L/kg, indicating distribution into total body water and tissues.
Oral bioavailability of mycophenolate mofetil is approximately 94% (converted to MPA). Intravenous: 100%.
Oral bioavailability of azathioprine is approximately 60-70% (range 27-82%) due to first-pass metabolism. Intravenous administration yields 100% bioavailability.
For GFR 10-50 m L/min: maximum 2 g daily; for GFR <10 m L/min: maximum 1 g daily.
GFR 50-80 m L/min: no adjustment. GFR 30-50 m L/min: reduce dose by 25% to 50%. GFR 10-30 m L/min: reduce dose by 50% to 75%. GFR <10 m L/min: avoid or use with extreme caution.
No dosage adjustment required for hepatic impairment. No Child-Pugh based modifications are established.
Child-Pugh class A: no adjustment. Child-Pugh class B: reduce dose by 50%. Child-Pugh class C: avoid use.
For ages 3 months to 18 years: 600 mg/m2 orally twice daily; maximum 2 g daily. Intravenous: same oral dose converted to IV.
2-5 mg/kg/day IV or oral, divided every 12-24 hours; dose based on body weight (mg/kg).
No specific dose adjustment, but start at lower end of dosing range due to age-related renal impairment. Monitor for adverse effects.
Start at lower end of dosing range; monitor renal function and adjust accordingly. Consider reduced initial dose (e.g., 1 mg/kg/day) due to age-related decreased renal function.
Increased risk of pregnancy loss and congenital malformations; must avoid pregnancy during therapy. Use in women of childbearing potential only if contraception is used and pregnancy is excluded.
MALIGNANCY: Immunosuppression increases risk of lymphoma and other malignancies, particularly skin cancers. Monitor for neoplasia, especially in renal transplant patients.
Increased susceptibility to infections (e.g., CMV, BK virus), lymphomas, and other malignancies; dose reduction in renal impairment; avoid use with azathioprine; monitor for neutropenia, GI bleeding, and progressive multifocal leukoencephalopathy.
Hematotoxicity (leukopenia, thrombocytopenia, anemia) - monitor CBC. Hepatotoxicity - monitor liver function tests. Increased infection risk. Pancreatitis. Hypersensitivity reactions. Increased risk of malignancy (skin cancer, lymphoma). Use with caution in renal/hepatic impairment. Test for TPMT deficiency before use.
Hypersensitivity to mycophenolate mofetil or mycophenolic acid; women who are pregnant or planning pregnancy (unless no alternative); women of childbearing potential not using effective contraception.
Hypersensitivity to azathioprine or 6-mercaptopurine. Severe active infection. Pregnancy (FDA Category D), especially first trimester. Lactation. Concomitant use with allopurinol (unless dose adjusted). TPMT deficiency (increased risk of severe myelotoxicity).
Avoid taking with food high in fat or protein as it may reduce absorption. Grapefruit juice may decrease mycophenolate absorption; avoid concurrent consumption. No specific dietary restrictions besides maintaining consistent intake with meals.
Avoid raw or undercooked meats and fish to reduce infection risk; no specific dietary restrictions; grapefruit juice has no known interaction.
First trimester exposure is associated with a high risk of congenital malformations, including craniofacial defects (cleft lip/palate), cardiovascular anomalies, and neural tube defects. Second and third trimester exposure may cause intrauterine growth restriction, preterm delivery, and neonatal immunosuppression. Mycophenolic acid is contraindicated in pregnancy unless no alternative treatment is available.
FDA Category D. Hematologic toxicity and immunosuppression in the neonate. Increased risk of congenital malformations (cleft palate, skeletal anomalies) and fetal growth restriction. First trimester exposure associated with highest risk; second and third trimester risks include intrauterine growth restriction and preterm birth.
M/P ratio is unknown. Mycophenolic acid is excreted into breast milk in small amounts; however, due to potential for serious adverse effects in the nursing infant, including immunosuppression and growth delay, breastfeeding is not recommended during therapy.
Contraindicated during breastfeeding due to potential immunosuppression and hematologic toxicity in the nursing infant. M/P ratio: Not established.
No specific dose adjustments are established due to lack of pharmacokinetic data in pregnancy. Systemic exposure may be reduced due to increased plasma volume and metabolism; however, due to teratogenicity, use is contraindicated. If unavoidable, consider monitoring mycophenolic acid trough levels and adjust dose to maintain therapeutic range (1.0–3.5 mg/L), but safety is not established.
Azathioprine dose may need to be reduced due to increased clearance in pregnancy; monitor 6-thioguanine nucleotide levels. Empiric dose adjustments not standardized; titrate to maintain therapeutic effect while minimizing myelotoxicity.
Mycophenolate mofetil (CELLCEPT) is a prodrug of mycophenolic acid, an inosine monophosphate dehydrogenase inhibitor. It is used for prophylaxis of organ rejection in renal, cardiac, and hepatic transplant recipients. Monitor for leukopenia, neutropenia, and infections. Dose adjustment required in renal impairment (GFR <25 m L/min). Avoid use in pregnancy (Pregnancy Category D). Contraindicated in hypersensitivity to mycophenolate. Intravenous administration should be over 2 hours. Monitor for GI bleeding and CMV infection.
Monitor CBC and LFTs weekly for first month, then biweekly for next 2 months, then monthly; dose reduction required with allopurinol coadministration (reduce to 25% of usual dose); screen for TPMT and NUDT15 deficiency before initiating therapy; avoid live vaccines; increased risk of lymphoproliferative disorders; use sun protection due to photosensitivity; pregnancy category D.
Take exactly as prescribed, with or without food. Do not crush or chew capsules.,Avoid sunlight and use sunscreen due to increased risk of skin cancer.,Report any signs of infection (fever, sore throat, unusual bleeding or bruising).,Use effective contraception during treatment and for 6 weeks after stopping if female of childbearing potential.,Do not breastfeed while taking this medication.,Store at room temperature, away from moisture and heat.
Take exactly as prescribed, do not stop without consulting your doctor.,Report any signs of infection (fever, sore throat, easy bruising or bleeding) immediately.,Use effective contraception during treatment and for at least 3 months after stopping.,Avoid live vaccines (e.g., MMR, varicella, nasal flu) while on this medication.,Limit sun exposure and use broad-spectrum sunscreen and protective clothing.,Do not take allopurinol without your doctor's knowledge.,Attend all scheduled blood tests to monitor for side effects.,May cause nausea; take with food if upset stomach occurs.
No interactions on record
"Azathioprine may reduce the therapeutic efficacy and cardiotoxic effects of digitoxin by accelerating its metabolism through induction of cytochrome P450 enzymes, particularly CYP3A4. This interaction can lead to decreased digitoxin serum concentrations, potentially resulting in loss of heart rate control in patients with atrial fibrillation or heart failure. Conversely, the cardiotoxic risk of digitoxin is diminished, but the therapeutic goal may be compromised."
"Azathioprine and fingolimod both suppress lymphocyte function, leading to additive or synergistic immunosuppression. This combination increases the risk of severe infections, including opportunistic infections, due to profound immune system suppression. Clinically, patients may present with prolonged lymphopenia, increased susceptibility to infections, and potential reactivation of latent viruses such as JC virus (causing progressive multifocal leukoencephalopathy) or cytomegalovirus."
"Azathioprine, an immunosuppressant that acts as a prodrug for 6-mercaptopurine, can increase the myelosuppressive effects of benazepril, an ACE inhibitor. This interaction is likely due to additive bone marrow suppression, leading to an elevated risk of leukopenia, anemia, and thrombocytopenia, especially in patients with renal impairment or concomitant use of other myelosuppressive agents."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CELLCEPT vs AZATHIOPRINE SODIUM, answered by our medical review team.
CELLCEPT is a Immunosuppressant that works by Mycophenolate mofetil is a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), inhibiting de novo purine synthesis in T and B lymphocytes, thereby suppressing lymphocyte proliferation.. AZATHIOPRINE SODIUM is a Immunosuppressant that works by Azathioprine is a prodrug of 6-mercaptopurine. It inhibits purine synthesis by interfering with the synthesis of DNA, RNA, and cellular proteins, thereby suppressing immune responses.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CELLCEPT and AZATHIOPRINE SODIUM depend on the specific clinical indication. These are both Immunosuppressant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CELLCEPT is: Oral: 1-2 g daily in two divided doses. Intravenous: 1-2 g daily in two divided doses as a 2-hour infusion.. The standard adult dose of AZATHIOPRINE SODIUM is: 1-2 mg/kg/day IV or oral, initially; maintenance 0.5-1 mg/kg/day IV or oral. For severe organ rejection: 3-5 mg/kg/day IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CELLCEPT and AZATHIOPRINE SODIUM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CELLCEPT is classified as Category C. First trimester exposure is associated with a high risk of congenital malformations, including craniofacial defects (cleft lip/palate), cardiovascular anomalies, and neural tube de. AZATHIOPRINE SODIUM is classified as Category D/X. FDA Category D. Hematologic toxicity and immunosuppression in the neonate. Increased risk of congenital malformations (cleft palate, skeletal anomalies) and fetal growth restrictio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.